Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
MEDP vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
MEDP vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $12.19B | $29.95B |
| Revenue (TTM) | $2.68B | $16.63B |
| Net Income (TTM) | $460M | $1.39B |
| Gross Margin | 29.1% | 26.1% |
| Operating Margin | 21.0% | 13.9% |
| Forward P/E | 25.1x | 13.9x |
| Total Debt | $250M | $16.17B |
| Cash & Equiv. | $497M | $1.98B |
MEDP vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Medpace Holdings, I… (MEDP) | 100 | 459.8 | +359.8% |
| IQVIA Holdings Inc. (IQV) | 100 | 118.0 | +18.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MEDP vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MEDP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.26
- Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
- 14.4% 10Y total return vs IQV's 167.5%
IQV is the clearest fit if your priority is valuation efficiency.
- PEG 0.34 vs MEDP's 0.79
- Lower P/E (13.9x vs 25.1x), PEG 0.34 vs 0.79
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs IQV's 5.9% | |
| Value | Lower P/E (13.9x vs 25.1x), PEG 0.34 vs 0.79 | |
| Quality / Margins | 17.2% margin vs IQV's 8.3% | |
| Stability / Safety | Beta 1.26 vs IQV's 1.33, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +47.8% vs IQV's +20.7% | |
| Efficiency (ROA) | 24.8% ROA vs IQV's 4.7%, ROIC 154.9% vs 8.7% |
MEDP vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MEDP vs IQV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MEDP leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 6.2x MEDP's $2.7B. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to IQV's 8.3%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.7B | $16.6B |
| EBITDAEarnings before interest/tax | $577M | $3.5B |
| Net IncomeAfter-tax profit | $460M | $1.4B |
| Free Cash FlowCash after capex | $745M | $2.7B |
| Gross MarginGross profit ÷ Revenue | +29.1% | +26.1% |
| Operating MarginEBIT ÷ Revenue | +21.0% | +13.9% |
| Net MarginNet income ÷ Revenue | +17.2% | +8.3% |
| FCF MarginFCF ÷ Revenue | +27.8% | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +26.5% | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.6% | +15.0% |
Valuation Metrics
IQV leads this category, winning 7 of 7 comparable metrics.
Valuation Metrics
At 22.5x trailing earnings, IQV trades at a 19% valuation discount to MEDP's 27.9x P/E. Adjusting for growth (PEG ratio), IQV offers better value at 0.56x vs MEDP's 0.88x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $12.2B | $29.9B |
| Enterprise ValueMkt cap + debt − cash | $11.9B | $44.1B |
| Trailing P/EPrice ÷ TTM EPS | 27.93x | 22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.13x | 13.89x |
| PEG RatioP/E ÷ EPS growth rate | 0.88x | 0.56x |
| EV / EBITDAEnterprise value multiple | 21.21x | 12.87x |
| Price / SalesMarket cap ÷ Revenue | 4.82x | 1.84x |
| Price / BookPrice ÷ Book value/share | 27.45x | 4.62x |
| Price / FCFMarket cap ÷ FCF | 17.87x | 14.60x |
Profitability & Efficiency
MEDP leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $22 for IQV. MEDP carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), MEDP scores 6/9 vs IQV's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +120.9% | +22.1% |
| ROA (TTM)Return on assets | +24.8% | +4.7% |
| ROICReturn on invested capital | +154.9% | +8.7% |
| ROCEReturn on capital employed | +65.7% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.55x | 2.44x |
| Net DebtTotal debt minus cash | -$247M | $14.2B |
| Cash & Equiv.Liquid assets | $497M | $2.0B |
| Total DebtShort + long-term debt | $250M | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 3.10x |
Total Returns (Dividends Reinvested)
MEDP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MEDP five years ago would be worth $26,038 today (with dividends reinvested), compared to $7,632 for IQV. Over the past 12 months, MEDP leads with a +47.8% total return vs IQV's +20.7%. The 3-year compound annual growth rate (CAGR) favors MEDP at 26.8% vs IQV's -2.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -25.3% | -21.7% |
| 1-Year ReturnPast 12 months | +47.8% | +20.7% |
| 3-Year ReturnCumulative with dividends | +103.7% | -7.0% |
| 5-Year ReturnCumulative with dividends | +160.4% | -23.7% |
| 10-Year ReturnCumulative with dividends | +1435.8% | +167.5% |
| CAGR (3Y)Annualised 3-year return | +26.8% | -2.4% |
Risk & Volatility
Evenly matched — MEDP and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
MEDP is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 71.4% from its 52-week high vs MEDP's 67.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.33x |
| 52-Week HighHighest price in past year | $628.92 | $247.05 |
| 52-Week LowLowest price in past year | $284.10 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +67.9% | +71.4% |
| RSI (14)Momentum oscillator 0–100 | 41.5 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 372K | 1.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MEDP as "Hold" and IQV as "Buy". Consensus price targets imply 27.9% upside for IQV (target: $226) vs 16.9% for MEDP (target: $499).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $498.86 | $225.63 |
| # AnalystsCovering analysts | 19 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +7.5% | +4.2% |
MEDP leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IQV leads in 1 (Valuation Metrics). 1 tied.
MEDP vs IQV: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MEDP or IQV a better buy right now?
For growth investors, Medpace Holdings, Inc.
(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 5x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MEDP or IQV?
On trailing P/E, IQVIA Holdings Inc.
(IQV) is the cheapest at 22. 5x versus Medpace Holdings, Inc. at 27. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 13. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus Medpace Holdings, Inc. 's 0. 79x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MEDP or IQV?
Over the past 5 years, Medpace Holdings, Inc.
(MEDP) delivered a total return of +160. 4%, compared to -23. 7% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: MEDP returned +1436% versus IQV's +167. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MEDP or IQV?
By beta (market sensitivity over 5 years), Medpace Holdings, Inc.
(MEDP) is the lower-risk stock at 1. 26β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 6% more volatile than MEDP relative to the S&P 500. On balance sheet safety, Medpace Holdings, Inc. (MEDP) carries a lower debt/equity ratio of 55% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MEDP or IQV?
By revenue growth (latest reported year), Medpace Holdings, Inc.
(MEDP) is pulling ahead at 20. 0% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Medpace Holdings, Inc. grew EPS 21. 0% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MEDP or IQV?
Medpace Holdings, Inc.
(MEDP) is the more profitable company, earning 17. 8% net margin versus 8. 3% for IQVIA Holdings Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 14. 0% for IQV. At the gross margin level — before operating expenses — MEDP leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MEDP or IQV more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus Medpace Holdings, Inc. 's 0. 79x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 13. 9x forward P/E versus 25. 1x for Medpace Holdings, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 27. 9% to $225. 63.
08Which pays a better dividend — MEDP or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MEDP or IQV better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1436% 10Y return). Both have compounded well over 10 years (MEDP: +1436%, IQV: +167. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MEDP and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.